Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats

Neurosci Lett. 2000 Oct 20;293(1):65-8. doi: 10.1016/s0304-3940(00)01488-9.

Abstract

In the brain, metallothionein (MT)-III exhibits a free radical scavenging activity. Here we examined the expression of MT-III mRNA in the basal ganglia of 6-hydroxydopamine (6-OHDA)-lesioned hemi-parkinsonian rats and its regulation by levodopa. The level of MT-III mRNA was significantly decreased in the striatum of 6-OHDA-lesioned side. Levodopa treatment significantly increased the expression of striatal MT-III mRNA in the non-lesioned side, but showed no significant effect in the 6-OHDA-lesioned side. These results suggest that the regulation of MT-III mRNA may be related to the progressive degeneration in parkinsonism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiparkinson Agents / pharmacology*
  • Basal Ganglia / metabolism*
  • Corpus Striatum / metabolism
  • Levodopa / pharmacology*
  • Male
  • Metallothionein 3
  • Nerve Tissue Proteins / genetics*
  • Oxidopamine
  • Parkinsonian Disorders / chemically induced
  • Parkinsonian Disorders / metabolism*
  • RNA, Messenger / metabolism*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Antiparkinson Agents
  • Metallothionein 3
  • Nerve Tissue Proteins
  • RNA, Messenger
  • Levodopa
  • Oxidopamine